01.16 Hypermutation in Breast Cancer: A Potential Marker for Immunotherapy?

H. M. Poushay1, M. Asaoka1, K. Takabe1  1Roswell Park Cancer Institute,Department Of Surgical Oncology,Buffalo, NY, USA

Introduction:
Immunotherapy has revolutionized treatment of many cancers, although its role in breast cancer treatment has yet to be well-established. Immune checkpoint inhibitors (ICIs) have demonstrated significant therapeutic responses across a variety of cancers, and may prolong overall survival in tumors with high mutation loads. One such ICI is the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitor, which targets the PD-1/PD-L1 pathway, resulting in restoration of the immune system’s anti-tumor response. To investigate the potential role of ICIs in the treatment of breast cancer, we sought to compare hypermutated breast cancers to non-hypermutated breast cancers. We hypothesized that hypermutated breast cancers would have increased heterogeneity, leading to an increased presence of tumor-infiltrating lymphocytes (TILs), which has been shown to portend favorable response to immunotherapy.  We also hypothesized that the hypermutated group would have higher cytolytic activity and PD-1/PD-L1 activity; the latter has also been suggested as a predictor of cancer response to PD-1/PD-L1 inhibitor therapy.

Methods:

Genomic and clinical data of 1065 breast cancer patients were obtained from The Cancer Genome Atlas (TCGA) and the Pan-Cancer Atlas.

We defined hypermutated tumors as those with non-silent mutation rate greater than 3.0.

Cytolytic activity (CYT), T cell receptor (TCR) diversity, and tumor infiltrating immune cell composition were calculated by CIBERSORT. Categorical variables were compared by Fisher's exact test (p<0.05 considered significant).

Results:

Of the 1065 patients, 114 (10.7%) were identified as having hypermutated tumors. The incidence of hypermutation was more frequent in older patients (age ≥50 vs. <50; 12.1% vs. 7.4%; p=0.03; odds ratio [OR]=1.7), in ER-negative compared to ER-positive tumors (18.6% vs. 8.8%; p <0.01; OR=2.4), but was not associated with cancer stage (p=0.485) or HER2 receptor status (p=0.079). Intra-tumor heterogeneity was higher in hypermutated tumors (p=0.014). Activated CD4 T-cells (p<0.001), macrophage M1 (p<0.001) and gamma delta T-cells (p<0.001) were higher in hypermutated tumors, whereas immune restraining regulatory T cells were lower (p=0.004). Reflecting the infiltration of immune activating cells, gene expression associated with TILs (p<0.001) and TCR diversity (p<0.001) were higher in the hypermutated group. Expression of immune checkpoint molecules PD-1 (p<0.001) and PD-L1 (p<0.001) were increased in the hypermutated tumor group. Finally, immune cytolytic activity was higher in the hypermutated group (p<0.001).

Conclusion:

The results support our hypothesis that hypermutation breast cancer tumors have increased heterogeneity and cytolytic activity, and increased PD-1/PD-L1 activity. Given these findings, further study is warranted to investigate the potential role of ICIs in breast cancer treatment in selected breast cancer patients.

01.15 MYC expression but not Amplification Associates with Worse Outocome in Triple-Negative Breast Cancer

E. Katsuta1, L. Yan2, K. Takabe1  1Roswell Park Cancer Institute,Breast Surgery, Department Of Surgical Oncology,Buffalo, NY, USA 2Roswell Park Cancer Institute,Department Of Biostatistics And Bioinformatics,Buffalo, NY, USA

Introduction: The use of clinical targeted DNA-sequencing to detect genomic alterations, including mutation and copy number alterations has become a routine in clinical practice for targeted therapy. However, the interpretation of the results in each gene is still understudied. MYC is one of the essential oncogenes and it plays a crucial role in regulation of the cell cycle and proliferation in various types of cancers including Triple-Negative Breast Cancer (TNBC). It is known that MYC amplification and high expression are associated with TNBC; however, the difference between a MYC amplified vs high expressing tumors in TNBC is not fully elucidated.

Methods:  Clinical and genomic data, including mRNA and Genomic Identification of Significant Targets in Cancer (GISTIC), were obtained from The Cancer Genome Atlas (TCGA) through cBioportal. MYC amplification was defined based upon copy-number GISTIC; GISTIC 2 was defined as tumor with amplification, remaining GISTIC -1, 0 and 1 were defined as tumor without amplification.

Results: Among 1080 patients with DNA copy-number data, 229 tumors (21.2%) showed MYC amplification, which was the most common copy-number alteration in the whole TCGA breast cancer cohort. Although MYC mRNA expression level was higher in MYC amplified tumors compared to non-amplified tumors (p<0.001), the mRNA expression levels were highly overlapped between amplified and non-amplified tumors. MYC amplification (p=0.112) as well as high expression (p=0.390) were not associated with overall survival (OS) in the whole cohort. 156 patients (15.5%) were classified as TNBC based on ER, PgR, immunohistochemistry status and HER2 immunohistochemistry and FISH method. In agreement with previous reports, there was greater proportion of TNBC subtypes in MYC amplified tumors (p<0.001), as well as in MYC high expressing tumors (p<0.001). Thus, we focused on TNBCs. There was no significant difference in MYC mRNA expression level between MYC amplified and non-amplified tumors in the TNBCs (p=0.074). Interestingly, none of the clinicopathological demographics were associated with either MYC amplification or high expression. However, high expression of MYC was significantly associated with worse OS (5-year OS rates: 61.6% vs 78.3%, p=0.026), whereas MYC amplification was not associated with OS (5-year OS rates: 75.7% vs 70.9%, p=0.515) in TNBC. Gene Set Enrichment Analysis (GSEA) demonstrated that MYC target gene sets (v1; p<0.001, v2; p<0.001) as well as cell cycle related gene sets, including E2F targets (p=0.013) and G2/M check point (p=0.018) gene sets, and WNT/beta-catenin gene set (p=0.017) were significantly enriched in MYC high expressing tumors, whereas out of 50 hall mark gene sets, none of them were enriched in MYC amplified tumors.

Conclusion: TNBCs with MYC higher expression, but not amplification, has worse prognosis in TNBC. It is important to consider that amplification is not always equal to high expression in some genes.

 

01.14 Expanding the Application of Serial Section Electron Microscopy (SSEM): Exploring Nerve Regeneration

J. Leckenby1,3, M. Chacon1, A. Grobbelaar3, J. Lichtman2  1University Of Rochester,Plastic Surgery,Rochester, NY, USA 2Harvard School Of Medicine,Molecular And Cell Biology,Cambridge, MA, USA 3Royal Free Hospital NHS Foundation Trust,Plastic Surgery,London, LONDON, United Kingdom

Introduction:  
Peripheral nerve assessment has traditionally been studied through histological and immunological staining techniques in a limited cross-sectional modality. The introduction of transgenic species, such as YFP-H mice, has greatly increased our ability to observe axonal regeneration and subjectively comment on behavior. However, detailed analysis is still difficult to assess with either of these methods and understanding cellular interactions is almost impossible. A new application of serial section electron microscopy (SSEM) is presented to overcome these limitations and open the application of this technique to other areas of pathology.

Methods:
Direct nerve repairs (DNR) were performed on the posterior auricular nerve of transgenic YFP-H mice. Six weeks post-operatively the nerves were imaged using confocal fluorescent microscopy then excised and embedded in resin. Resin blocks were sequentially sectioned at 100nm and sections were serially imaged with an electron microscope (Magellan 400L, FEI) utilizing the following parameters: 100nm pixel size, 200ns Dwell Time, 8k x 8k pixel field of view with 7.0kV and 26nA.  Images were aligned and auto-segmented to allow for 3D rendering using 3D Studio Max (Autodesk). 

Results:
Basic morphometry and axonal counts were fully automated. Using full 3D reconstructions, the relationships between the axons, the Nodes of Ranvier, and Schwann cells could be fully appreciated (See Fig. 1). The quality of regeneration could be examined throughout the entire dataset providing a comprehensive analysis. The interactions of individual axons with their surrounding environment could be visualized and explored in a virtual three dimensional space.

Conclusion:
SSEM allows the detailed pathway of the regenerating axon to be visualized in a 3D virtual space in comparison to isolated individual traditional histological techniques. Fully automated histo-morphometry can now give accurate axonal counts, provide information regarding the quality of nerve regeneration and reveal the cell-to-cell interaction at a super-resolution scale. It is possible to fully visualize and ‘fly-through’ the nerve to help understand the behavior of a regenerating axon within its environment. Having established this technique it provides future opportunities to evaluate the affect different treatment modalities have on the neuro-regenerative potential and help us understand the impact different surgical techniques have when treating nerve injuries.  Further investigations are being carried out to determine whether SSEM can be used to analyze cellular interactions in disease processes such as infection or tumor formation.

01.13 LCN2, CD133, CD151, TWIST1, EPHA2 are Breast Cancer Metastases Markers For Organ Specific Relapse

A. -. Maiti1, M. Okano1, I. Okano1, T. Kawaguchi1, K. Takabe1, N. Hait1, A. Maiti1  1Roswell Park Cancer Institute,Surgical Oncology,Buffalo, NY, USA

Introduction: ~~Breast cancer most often recurs and metastasizes to the distal organs that had their primary tumors surgically excised.  Functional analysis of organ-specific metastasis genes suggested that there might be two different categories of metastasis genes. One group of genes has the role in tumor growth and survival besides their metastasis function while another group of genes only have a specific role in facilitating adaptation of tumor cells at distant sites and do not have a clear role in promoting primary tumor growth.In this study, we assessed the specific cancer-related gene expression changes occurring with metastatic breast cancer recurrence to distant organs comparing with non-metastatic breast cancer.

Methods: ~~RNA-sequencing was done using two cell lines 4T1-luc2 that can only metastasize to lung and 4T1.2-luc2 metastasized to bone and lung suggested that at least 50 genes which are statistically highly expressed in 4T1.2-luc2 compared to 4T1-luc2 cells. Out of which only a few genes well established for cancer metastasis biology include ANGPTL77, SERPINE2, TSPAN11, ESM1, LCN2 which expressed over 8 fold in 4T1.2-luc2 compared to 4T1-luc2 cells. A metastatic syngeneic mouse model was developed and metastatic growth to distant organs was monitored using IVIS and MRI imaging after the primary tumor was surgically excised from mice.

Results:~~Our animal model tumor molecular analysis data revealed that LCN2 (7 fold) and CD133 (above 20 fold) over-expressed in the spine and bone compared to the primary or lung met lesions formed by 4T1.2-luc2. Conversely, LCN2 and CD133 genes are downregulated in breast cancer lung metastasis tissues, while CD151, EPHA2, and TWIST1 genes highly overexpressed in lung metastatic lesion compared to primary, bone or spine.  Further, the RNA-seq data of patient samples explained that LCN2, CD133 expressions are significantly higher (8 out of 10 patients) in advanced breast cancer bone metastases compared with matching non-metastatic breast cancer.

Conclusion:~~Our data suggested that LCN2, CD133 would be a prognostic marker for breast cancer spinal bone metastasis, while CD151, TWIST1, EPHA2 would be a prognostic marker for lung metastasis and organ-specific relapse.

 

01.12 Irreversible Proteasome Inhibitor Regulate CDK Inhibitor p21 & c-Jun Kinase in MDA-MB-231Cancer Cells

L. S. CHATURVEDI1,2,3, D. VYAS1,3  1SAN JOAQUIN GENERAL HOSPITAL,SURGERY,FRENCH CAMP, CALIFORNIA, USA 2CALIFORNIA NORTHSTATE UNIVERSITY,PHARMACEUTICAL SCIENCES AND BIOMEDICAL SCIENCES,ELK GROVE, CALIFORNIA, USA 3CALIFORNIA NORTHSTATE UNIVERSITY,COLLEGE OF MEDICINE,ELK GROVE, CALIFORNIA, USA

Introduction:

It is estimated that one million cases of breast cancer are diagnosed annually worldwide. Of these, approximately 12-20% are of the triple-negative breast cancer (TNBC) that do not express receptors for estrogen (ER), progesterone (PR) or human epidermal growth factor receptor 2 (HER2). TNBC is typically treated with a combination of other therapies such as chemotherapy, radiation, and surgery. Therefore, there is urgent need of new therapy for TNBC patients. Carfilzomib (CFZ) is a selective irreversible second-generation proteasome inhibitor being used for the treatment of relapsed and refractory multiple myeloma as the anticancer therapy. We have previously reported antiproliferative and apoptotic effects of CFZ alone or in combination with Doxorubicin (DOX) on human TNBC-MDA-MB-231 cancer cells. Overexpression of cyclin-dependent kinase inhibitor CDKN1A/p21Waf1/Cip1 and an elevated phosphorylation of stress-activated c-Jun NH2-terminal kinase has been reported in basal-types and TNBCs with poor prognosis. However, the role of CFZ in the regulation of CDKN1A/p21Waf1/Cip1 protein expression and c-Jun NH2-terminal kinase activation has not been determined in human TNBC-MDA-MB-231 cancer cells. Herein, we investigated the role of CFZ in the modulation of CDKN1A/p21Waf1/Cip1 and c-Jun NH2-terminal kinase activation in human TNBC-MDA-MB-231 breast cancer cells.

Methods:

Human TNBC-MDA-MB-231 cell-line, a model for TNBC was treated by various concentrations of CFZ alone, in a combination with DOX or vehicle control dimethyl sulfoxide (DMSO). Cell Counting Kit-8 (CCK-8) using WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium, monosodium salt) was used to detect cell viability. Annexin V-FITC apoptosis detection kit and flow cytometry were used to analyze the cell cycle. Western blot was used to detect the expression of cyclin-dependent kinase inhibitor CDKN1A/p21Waf1/Cip1 protein and phosphospecific c-Jun NH2-terminal kinase antibodies

Results:

We confirmed the antiproliferative and apoptotic effects of CFZ alone or in combination with DOX using CCK-8 viability and Annexin V-FITC apoptosis detection Kit respectively. The immunoblot analysis revealed that CFZ alone significantly inhibited CDKN1A/p21Waf1/Cip1 in a dose-dependent manner and as well as in a combination with DOX in comparison to vehicle control DMSO. Furthermore, CFZ alone and in a combination with DOX also significantly inhibited the phosphorylation of stress-activated c-Jun NH2-terminal kinase in human TNBC- MDA-MB-231 cancer cells.

Conclusion:

Our data suggest that irreversible proteasome inhibitor CFZ alone and in combination with DOX may induce apoptosis and inhibit proliferation by modulating CDKN1A/p21Waf1/Cip1 protein expression and phosphorylation of stress-activated c-Jun NH2-terminal kinase in human MDA-MB-231 breast cancer cells. Further investigation will encourage the potential use of CFZ alone and in the combination of DOX against tumors harboring drug-resistant phenotypes.

01.11 Levels of sphingolipids in plasma are elevated in breast cancer patients with lymph node metastasis

J. Tsuchida1, M. Nagahashi1, K. Moro1, M. Ikarashi1, Y. Koyama1, H. Ichikawa1, Y. Shimada1, J. Sakata1, T. Kobayashi1, H. Kameyama1, K. Takabe2,3, T. Wakai1  3University at Buffalo Jacobs School of Medicine and Biomedical Sciences, The State University of New York,Department Of Surgery,Buffalo, NEW YORK, USA 1Niigata University Graduate School of Medical and Dental Sciences,Division Of Digestive And General Surgery,Niigata, NIIGATA, Japan 2Roswell Park Comprehensive Cancer Center,Breast Surgery, Department Of Surgical Oncology,Buffalo, NEW YORK, USA

Introduction: A bioactive lipid mediator, sphingosine-1-phosphate (S1P) has emerged as a key regulatory molecule in cancer progression. S1P exerts its regulatory functions after it is secreted out of cancer and stromal cells and regulates various cellular functions, such as cell proliferation, migration, and angiogenesis. We previously demonstrated that S1P is a crucial mediator of breast cancer-induced angiogenesis and lymphangiogenesis and promotes metastasis to the lymph nodes and to the lung (Cancer Res 2012, Cancer Res 2018). We have also reported that high S1P levels in the tumor are associated with lymph node metastasis in breast cancer patients (J Surg Res 2016), however, the role of S1P in plasma has not been fully investigated in breast cancer patients. In this study, we studied the levels of sphingolipids including S1P in plasma from breast cancer patients to reveal their clinical significance.

Methods: A retrospective analysis was conducted on 88 breast cancer patients, who received curative surgery in our institute. Among them, 18 patients received neoadjuvant chemotherapy. The plasma from the patients were obtained immediately prior to the operation. Sphingolipids, including sphingosine, dihydro-sphingosine, S1P and dihydro-S1P, were determined by liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS). The levels of sphingolipids were analyzed with patients’ clinical demographics, and statistical analysis was performed with the Mann- Whitney U-test.

Results: The levels of sphingolipids including sphingosine, dihydro-sphingosine, S1P, dihydro-S1P were detected successfully in the plasma from all the breast cancer patients. Levels of S1P in patients with neoadjuvant chemotherapy (N=18, median 1144, range 657–1555 pmol/ml) was significantly higher than that in patients without neoadjuvant chemotherapy (N=70, median 797, range 448–1827 pmol/ml) (P<0.0001). Levels of sphingosine in patients with neoadjuvant chemotherapy (median 25, range 17–61 pmol/ml) was significantly higher than that in patients without neoadjuvant chemotherapy (median 20, range 9–76 pmol/ml) (P=0.0143). Among the 70 patients without neoadjuvant chemotherapy, S1P levels in patients with pathologically proven lymph node metastasis (N=17, median 884, range 698–1275 pmol/ml) was significantly higher than that in patients without lymph node metastasis (N=53, median 758, range 448–1827 pmol/ml) (P=0.0091). Sphingosine levels in the patients with pathologically proven lymph node metastasis (median 22, range 12–76 pmol/ml) was also significantly higher than that in the patients without lymph node metastasis (median 19, range 9–63 pmol/ml) (P=0.0340).

Conclusion: Our results suggest that S1P in plasma plays an important role during the process of lymph node metastasis in breast cancer patients. It also implicates a possibility of plasma S1P as a biomarker for lymph node metastasis.

 

01.10 Establishment of Metastatic Breast Cancer to the Lung by Surgical Implantation

M. Oshi1, M. Okano1, A. L. Butash1, K. Takabe1  1Roswell Park Cancer Institute,Department Of Surgical Oncology,Buffalo, NY, USA

Introduction: Although targeted therapies in primary breast cancer have significantly improved the survival rate in the last two decades, the challenge to improve the survival rate in patients with metastatic breast cancer still remains. Pre-clinical models play an important role in developing treatment strategies, but proper breast cancer metastasis models have not been established due to the difficulty and complication of the procedure. We developed the “thoracotomy” method in order to establish a breast cancer lung metastasis model, which is simple and resembles human lung metastasis. 

Methods: All work was performed in female NSG or bulb/c mice of age 8-12 weeks. PDX of lung metastasis model was made from patient-derived breast tumors. PDX breast tumors that had been passaged 3 times in mammary fat pads or lung metastasis tumor generated using 4T1 cell line were used. Tumors were diced to ~1 mm3 pieces using a sharp blade. 

Results: The right middle lobe was selected as an implantation site in order to allow the tumor to invade the lung and not the chest wall. In the “thoracotomy” method, the chest wall incision was made and tumor fragments were implanted using forceps and 8-0 nylon surgical suture. Another approach was to directly inject the minced tumor tissue 1mm below the lateral pleural surface of the middle lobe using a 23G needle. The incision was closed with a 6-0 surgical suture. An intrathoracic puncture was made with a 27G needle to withdraw the remaining air from the chest cavity. After the air had been withdrawn, a completely inflated lung could be seen through the thin chest wall. In the “non-thoracotomy” method, the minced tissue was injected into the mice lung through the chest wall with a 23G needle. One hour post-surgical survival rate was only 30% after “thoracotomy” method (non-fixing suture 9/30, fixing suture 8/30) due to open pneumothorax resulting from excessive wound tension and intercostal muscle cut through. All mice after “non-thoracotomy” method survived, but implantation in the chest wall was observed in 67% (4/6) of cases and the method achieved only 50% (3/6) of the accurate transplantation into the middle lung when performed preliminarily using the cell line.  To increase the survival rate with the “thoracotomy” method, we limited the incision size <10 mm and compared the outcome with the original incision group. Limited incision “thoracotomy” could significantly increase one hour post-surgical survival to 97% (29/30) (<10 mm vs. ≥10 mm: t test P = 0.003). 

Conclusion: By simple modifications of surgical techniques, we are able to establish an orthotopic lung metastasis mice model with almost zero operative mortality. Our orthotopic thoracotomy model has the potential to be a powerful tool for preclinical studies of breast cancer patients with lung metastases.

 

01.09 Optogenetic Stimulation of the Dorsal Motor Nucleus in the Brainstem Induces Increased Splenic Nerve Activity

A. M. Kressel1,3,4, T. Tsaava1, E. H. Chang1, Q. Chang1, V. A. Pavlov1,2, S. S. Chavan1,2, K. J. Tracey1,2  1The Feinstein Institute for Medical Research,Center For Biomedical Science,Manhasset, NEW YORK, USA 2The Feinstein Institute for Medical Research,Center For Bioelectronic Medicine,Manhasset, NEW YORK, USA 3Northwell Health,Department Of Surgery,Manhasset, NEW YORK, USA 4The Elmezzi Graduate School of Molecular Medicine,Manhasset, NEW YORK, USA

Introduction: The inflammatory reflex is a well-defined neural circuit composed of afferent and efferent vagus nerve fibers that both senses peripheral cytokine levels and regulates splenic tumor necrosis factor (TNF) production to maintain homeostasis. Previous studies have demonstrated that efferent vagus nerve signals originate both in the dorsal motor nucleus of the vagus (DMV) and in the nucleus ambiguus in the brainstem. The efferent arc of the inflammatory reflex relays functional signals from the efferent vagus nerve fibers to the splenic nerve, which, after entering the splenic parenchyma, modulates the release of acetylcholine from a subset of T-cells and a subsequent attenuation of TNF production from resident macrophages. Although this pathway has been extensively studied by us and other groups, the existence of a functional synapse between the vagus and splenic nerves remains controversial. Using optogenetics and neural recordings, we selectively studied the role of DMV cholinergic neurons in inducing splenic nerve activation.

Methods:  Using stereotactic guidance, a fiber optic cannula was inserted into the DMV of transgenic mice expressing channelrhodopsin under the choline acetyltransferase promoter (ChAT-ChR2-EYFP) and stimulation was applied (473nm laser, 20Hz, 25% duty cycle, 3 minutes, n=12/group). Splenic nerve activity was simultaneously recorded using a cuffed two-channel electrode. Next, to determine the contribution of the vagus nerve in transmitting signals generated in the DMV to the splenic nerve, we measured splenic nerve activity before and after chemically blocking the vagus nerve. Following recording of splenic nerve activity during DMV stimulation, 0.05% bupivacaine was applied to the vagus nerve to prevent further signal transduction, and splenic nerve activity was recorded again during DMV stimulation.

Results: Splenic nerve activity was significantly increased over baseline (p=0.0002) during optogenetic stimulation of the cholinergic fibers in the DMV (Figure 1). Administration of bupivacaine on the vagus nerve significantly attenuated splenic nerve activity during optogenetic stimulation of cholinergic fibers in the DMV (p=0.0091), demonstrating a functional synapse between the vagus and splenic nerves.

Conclusion: These studies reveal that cholinergic fibers originating in the DMV induce splenic nerve activation via the vagus nerve. Knowledge of the neural circuitry of the inflammatory reflex, coupled with our previous work on endotoxemia, will allow for therapeutic interventions for patients with inflammatory conditions.

01.08 Investigating Coordinate Roles for Estrogen and Integrin α3β1: Control of the Keratinocyte Secretome

L. A. DeFreest1, G. J. DeFreest-Rondeau1, L. Van De Water1, C. M. DiPersio1  1Albany Medical College,Department Of Surgery,Albany, NY, USA

Introduction: Integrins expressed in epidermal keratinocytes have important roles in cutaneous wound healing including paracrine stimulation of angiogenesis, regulation of proliferation and migration, and remodeling of extracellular matrix (ECM). Our laboratory has investigated roles of the laminin-binding integrin α3β1 in keratinocytes using both in vivo and in vitro models of wound healing. Our previous studies support a critical role for α3β1 in regulating the secretion of proteins into the extracellular milieu. Current data indicate a gene regulatory mechanism that involves crosstalk between α3β1 and estrogen responsive pathways in keratinocytes. Our long-term goal is to elucidate how α3β1 and estrogen coordinately regulate paracrine and autocrine signaling mechanisms that modulate the wound microenvironment to promote efficient wound healing.

Methods: For these studies, we have established a cell culture model consisting of mouse keratinocytes (MK cells), that are homozygous for a null mutation in the gene that encodes the α3 integrin subunit (i.e. lacking α3β1), or MK cells stably transfected with human α3  (i.e. MK α3+ cells, expressing α3β1). Conditioned media collected from these cells were compared by mass spectrometry (MS) to identify proteins secreted in an α3β1–dependent manner. Candidate proteins were then further evaluated by immunoblot to confirm and quantitate their expression/secretion. MK cells were also evaluated for the presence of estrogen receptor (ER) isoforms.

Results: 19 proteins identified by MS were upregulated more than 4-fold in medium from MK α3+ cells, compared with MK α3– cells. The secretion of lactoferrin, a protein whose production is controlled through an ER-dependent pathway, was up-regulated 18-fold in MK α3+ cells which was confirmed by immunoblot. Preliminary results indicate that MK cells express both ERα and ERβ. Furthermore, ERβ was increased in MK α3+ cells compared with MK α3- cells while ERα levels were similar in both cell lines. ERβ and ERα were increased in both MK lines by treatment with estrogen for 24 hours.

Conclusion: Proteomic analysis identified numerous secreted proteins that are upregulated by α3β1 indicating an important role for this integrin in controlling the keratinocyte secretome. Among these proteins, lactoferrin has been shown to modulate wound healing and has anti-microbial and immunomodulatory properties that make it an interesting candidate for further study. Lactoferrin is known to be induced by estrogen signaling, suggesting an unexplored intersection of pathways governed by integrins and ER. In particular, regulation of ERβ levels downstream of α3β1 may be a novel intracellular signaling pathway to regulate production of paracrine factors which in turn, modulate the wound microenvironment.

01.07 Characterization of Toll-Like Receptors in the Larynx: Implications for Inflammation

A. M. Mechler-Hickson1, M. Gowda1, S. L. Thibeault1  1University Of Wisconsin,Department Of Surgery, Division Of Otolaryngology – Head And Neck Surgery,Madison, WI, USA

Introduction:
The larynx is of vital importance in humans, contributing to breathing, swallowing, and phonation. It is also uniquely positioned at both the junction of the respiratory and GI tracts and the immunological boundary between the upper and lower respiratory systems. Due to their position, the vocal folds (VF), which are housed in the larynx, are exposed to a wide array of inhaled and ingested challenges. There is evidence that cells in the VF play a role in responding to these challenges: TLR1-6, TLR8 and TLR9 have been found in VF fibroblasts, the primary cell type of the lamina propria. Additionally, the majority of VF diseases are inflammatory in nature and have large economic and social consequences for patients. Despite the importance of the VF, and the inflammatory etiology of much of VF disease, mechanisms of host immunity in the larynx are ill-defined, and treatment of these inflammatory disorders is largely empiric. We worked to characterize toll-like receptors (TLR) 1-9, integral receptors in the innate immune system, in murine VF tissue, as mice are frequently used as a model species for humans, and in human VF epithelial cells.

Methods:
In order to localize TLR1-9 in murine VF tissue, excised larynges were coronally sectioned and processed for immunohistochemistry. Primary antibodies against TLR1-9 were used. An α-IgG secondary antibody was then applied, and diaminobenzidine was used as a staining agent. Staining was completed in biological and technical triplicate for each of the 9 antibodies with positive and negative controls.

Transcript levels of TLR1-9 were investigated in immortalized human VF epithelial cell lines. Cells were seeded into 6-well plates at a density of 1.5E5/mL and grown to near confluence. Cells were then treated with or without 5μg/mL LPS for 24 hours in wells intended for RT-PCR, and with or without 5μg/mL LPS for 8 hours in wells intended for ELISA analysis of IL-8, a downstream product of TLR activation. RT-PCR and ELISA were performed in biological and technical triplicate.

Results:
TLR1-9 were found in the epithelial cell layer of VF (Fig. 1). At the time of abstract submission results are ongoing, but we expect to find TLR1-9 in VF epithelial cells, with decreased expression for TLR6 -7. When treated with LPS we expect to find increased TLR expression and IL-8 levels, similarly to prior work in VF fibroblasts.

Conclusion:
This study localized TLR1-9 in VF epithelium. Exploring this, and how TLR expression and downstream cytokine activation differs between normal epithelial cells and those exposed to inflammatory stimuli, better elucidates how laryngeal epithelium responds to the variety of insults it is exposed to and may provide targets for treatment of airway disease.

01.06 Generation and Characterization of Novel Orthotopic and Metastatic Adrenocortical Carcinoma Xenografts

M. K. Penny1, K. J. Basham2, S. Chukkapalli3, Y. Yu3, M. J. Hoenerhoff4, G. D. Hammer2,5, E. A. Newman3  1University Of Michigan,Doctoral Program In Cancer Biology,Ann Arbor, MI, USA 2University Of Michigan,Department Of Internal Medicine, Division Of Metabolism, Endocrinology And Diabetes,Ann Arbor, MI, USA 3University Of Michigan,Department Of Surgery, C.S. Mott Children’s And Women’s Hospital, Mott Solid Tumor Oncology Program,Ann Arbor, MI, USA 4University Of Michigan,Unit For Laboratory Animal Medicine,Ann Arbor, MI, USA 5University Of Michigan,Endocrine Oncology Program, Rogel Cancer Center,Ann Arbor, MI, USA

Introduction:  Adrenocortical carcinoma (ACC) is a rare and often aggressive cancer, with a 5-year survival rate of 15% for those diagnosed with advanced disease. Improved models of this disease are needed for predictive preclinical testing in vivo. Subcutaneous, renal subcapsular, and splenic xenograft models of ACC do not mimic the endogenous tumor microenvironment and require injection of high cell quantity (≥ 2.5×106) for efficient tumor engraftment. The development of orthotopic ACC xenograft models has been significantly limited by the complexity and morbidity of open surgery. In this study, we introduce a novel model of orthotopic ACC xenografts utilizing ultrasound-guided percutaneous implantation directly into the adrenal gland tissue, using as few as 200,000 cells.

Methods:  NCI-H295R and Y1 cells tagged with luciferase were percutaneously implanted into the adrenal of six to twelve-week old immunocompromised (NSG) mice. Mice were injected with 200,000 cells or 1,000,000 cells. Mice were monitored weekly by ultrasound and bioluminescent imaging and were euthanized and grossly dissected when tumors reached endpoint as defined by 150mmdetected by ultrasound or 1011photons/sec/cm2/sr detected by bioluminescent imaging. The liver, lung, spleen, kidney, adrenal, and lymph nodes were examined histologically.

Results: At endpoint, 89% of mice injected with 200,000 Y1 cells, 80% of mice injected with 200,000 NCI-H295R cells, and 75% of mice injected with 1,000,000 NCI-H295R cells had locally-invasive primary tumor in the adrenal and periadrenal space. Y1 metastases were found in the liver and lung. Average time to endpoint was 5.2 weeks, 8.9 weeks, and 9.6 weeks respectively. Bioluminescent photon flux and maximum radiance were not linearly correlated with tumor size in vivo.

Conclusion: Minimally invasive orthotopic xenografts of ACC cells in NSG mice are an efficient and reliable method of developing biologically relevant tumors. Successful tumor growth and spontaneous metastasis following injection of as few as 200,000 cells per adrenal demonstrates the advantage of modeling of the tumor microenvironment, as compared to subcutaneous and more recently published renal and splenic xenograft models, as well as orthotopic xenografts by open surgery. This model is an important improvement over standard ACC models for preclinical testing of new therapeutics and investigation of tumor biology.

 

01.05 Glucose Increases Hexokinase-2 Expression and Glycolytic Capacity in Anaplastic Thyroid Cancer

A. Aggarwal1, Z. Yuan1, M. A. Nehs1  1Brigham And Women’s Hospital,Department Of Surgery,Boston, MA, USA

Introduction: Anaplastic thyroid cancer (ATC) is a fatal malignancy characterized by rapidly dividing tumor cells that demonstrate dependence on glycolysis for energy metabolism.  We therefore sought to investigate the role of the glycolytic enzyme Hexokinase II (HK2) which is over expressed in many malignancies, including ATC.  We hypothesized that a high glucose environment would promote HK2 gene expression and drive glycolytic energy capacity. 

Methods: We cultured ATC cell lines (JL30 and 8505C) in high (25mM) or low (3mM) glucose concentrations for 96 hours.  We analyzed HK2 expression by Fluorescent in-situ hybridization (FISH). We performed Seahorse XF Glycolytic stress tests to determine glycolytic reserve under each condition.  

Results: We found higher and more variable HK2 expression in both ATC cell lines in the high glucose medium.  JL30 had an average of 3.1 HK2 signals [Range 2-14] with high glucose environment versus 2.7 signals [Range 0-5] in the low glucose environment. Seahorse metabolic analysis revealed a glycolytic capacity of 245.8 mpH/min in the high glucose environment versus 55.9 mpH/min (p<0.001). 8505 had an average of 2.9 HK2 signals in the high glucose environment versus 2.7 in the low glucose environment. Seahorse metabolic analysis revealed a glycolytic capacity of 45.5 mpH/min for high glucose treatment versus 25.8 mpH in the low glucose treatment (p<0.01).

Conclusion: Here we demonstrate that a high glucose environment increases the expression of the glycolytic enzyme Hexokinase II and that this was associated with a higher metabolic glycolytic reserve.  These studies are suggestive that the metabolism of anaplastic thyroid cancer cells is influenced by glucose concentrations.  Future studies are needed to determine if hyperglycemia influences tumor biology in vivo.   

 

01.04 Morphometric Parameters Vary with Age in the Adolescent and Adult Murine Small Intestine

C. J. Park1, M. P. Shaughnessy1, R. A. Cowles1  1Yale University School Of Medicine,Pediatric Surgery,New Haven, CT, USA

Introduction: Animal models allow researchers to study the effects of pharmacological and surgical interventions on the gastrointestinal (GI) mucosa. The benefits of using mice in the laboratory include low cost, ease of maintenance, and the applicability of a wide range of molecular tools. While the typical laboratory mouse reaches sexual maturity at 6-8 weeks, maturation ensues and mice are considered mature adults at 12-24 weeks. Meanwhile, the ages and genders of mice used for experiments reported in the literature vary drastically. We hypothesized that there is age-, but no gender-related variation in intestinal morphometric parameters, necessitating thoughtful experimental design.

Methods:  With IACUC approval, C56Bl/6J mice of varying ages (6, 12, 18, 24 weeks; n=4/group) were euthanized and the small intestine was isolated from the ligament of Treitz to the ileocecal valve. 2 cm segments of proximal, middle and distal small intestine were harvested and morphometric parameters assessed with microscopy. The distal segments were also stained for Ki67 to determine the crypt proliferation index (CPI). Secondary analysis comparing males and females (n=4/group) of matched ages was performed. Means were compared with Student’s t-test and variance of proportions was assessed with the Chi-squared test to a significance of p<0.05.  

Results: There was variation in the measured morphometric parameters (Figure). In the proximal small intestine, 18-week old mice had taller villi compared to 6- and 12-week old mice and 24-week old mice had taller villi compared to 12-week old mice. In the middle segments, 12-week old mice had taller villi compared to 18- and 24-week old mice. In the distal segments, 6-week old mice had taller villi compared to all other age groups. When comparing crypt depth, 6-week old mice had shallower crypts compared to all other groups in the proximal region and 12-week old mice had deeper crypts compared to 6- and 18-week old mice in the middle segments. CPI was statistically lower only in 12-week old mice compared to all other age groups. When comparing age-matched males and females, there was no difference in villus height or crypt depth except for the middle small intestine where villus height was greater in females compared to males. There was no difference in CPI between genders.

Conclusion: Small, but statistically significant, differences in villus height, crypt depth and crypt proliferation are present in mice of different ages, while fewer differences exist between male and female mice of the same age. Investigators studying the GI mucosa should be aware of these differences and aim for consistent age-matching of experimental animals in order to avoid errors and allow direct comparison between studies.

 

01.03 Preoperative Serum Levels of miR-210 Associated with Malignant Pheochromocytomas and Paragangliomas

S. Ruff1, R. Ayabe1, P. Malekzadeh1, M. Good1, M. Wach1, N. Nilubol1, E. Kebebew2, D. Patel1  1National Cancer Institute,Thoracic And Oncologic Surgery Branch,Bethesda, MD, USA 2Stanford University,Palo Alto, CA, USA

Introduction: There are no predictive clinical or laboratory tests that accurately distinguish between benign and malignant pheochromocytomas or paragangliomas (PPGLs). There is a link between dysregulated microRNAs and adverse prognosis in multiple malignancies. The overexpression of miR-210 has been found to be associated with the hypoxic state of the tumor microenvironment. The aim was to investigate if serum miR-210 levels could be used as a marker of malignancy in patients with PPGLs. 

Methods:  Patients with PPGLs (n=35) underwent an operation and had preoperative serum collected. Clinical demographics, genetic mutations, primary tumor size, postoperative biochemical response, and the development of recurrence or metastatic disease was prospectively collected. Total microRNA was extracted from the preoperative serum samples and miR-210 levels were measured by quantitative RT-PCR and normalized to miR-16. On univariable analysis primary tumor size, age, gender, race, body mass index, genetic mutation, miR-210 level, primary tumor site, and postoperative biochemical response from initial surgery was examined. Variables with a p-value <0.1 were included in a multivariable analysis.

Results: Of the 35 patients in our study, 10 underwent an operation for metastatic or recurrent disease and 25 did not develop recurrence or metastatic disease after their initial operation (median follow-up time of 65.7 months). Most patients had a primary pheochromocytoma (seven out of ten patients with metastasis/recurrence versus 17 out of 25 patients with benign pheochromocytomas). The most common mutation in the entire cohort was SDHB (n=10). There was a significantly lower serum miR-210 level in patients with metastasis/recurrence (2.3 versus 3.1, p=0.013) and larger primary tumor size in patients with a metastasis/recurrence (6.7 cm versus 4.1 cm, p=0.043) on univariable analysis. Age, gender, race, body mass index, genetic mutation, and postoperative biochemical response were not associated with recurrent or metastatic disease. Multivariable analysis did not show a significant difference for tumor size or miR-210 levels between these two groups.

Conclusion: Serum miR-210 expression levels were lower in patients with metastatic or recurrent disease at time of operation. Mir-210 expression may be a biomarker associated with metastatic or recurrent disease.

 

01.02 Exome Sequencing of Syndromic Adrenocortical Cancer Reveals Distinct Genetics from Sporadic ACC

N. G. Nicolson1, J. M. Healy1,2, R. Korah1, T. Carling1  1Yale University School Of Medicine,Yale Endocrine Neoplasia Laboratory, Department Of Surgery,New Haven, CT, USA 2Connecticut Children’s Medical Center,Hartford, CONNECTICUT, USA

Introduction:  Next-generation sequencing has provided detailed genetic profiles of sporadic adrenocortical carcinoma (ACC). However, the genetic landscapes of ACC developing in patients with tumor predisposition syndromes are not well-characterized, as they are excluded from large-scale studies. Understanding the somatic genomic events complementing the background of germline syndromes is critical for designing personalized therapeutics for these unique patients, and may shed light on the molecular underpinnings of both sporadic and syndromic ACC.

Methods:  ACC tissue and matched normal adrenal from a pediatric patient with clinically characterized Beckwith-Wiedemann syndrome were subjected to whole-exome sequencing (WES). Using multi-layered bioinformatics analysis, the WES data was compared to 21 sporadic ACCs which had also undergone WES. Single nucleotide variants (SNVs) of interest were subjected to damage prediction protocols to identify potential ACC drivers, and somatic copy number variations (CNVs) were also investigated.

Results: WES analysis revealed 8 relevant germline mutations in the index case, including a TP53 mutation previously associated with Li-Fraumeni syndrome. 25 potentially damaging somatic SNVs including multiple unique novel gene variants were identified. A damaging somatic mutation was identified in tumor suppressor CACNA2D3, a calcium channel gene in the same family as those previously reported to be mutated in some adrenocortical tumors. Although the mutation burden in the index case was similar to the sporadic ACC cohort, the total absence of CNVs was distinct from sporadic cases, all of which carried CNVs.

Conclusion: This study characterizes for the first time the genomic landscape of syndromic adrenocortical carcinoma of a patient with markers of both Beckwith-Wiedemann and Li-Fraumeni syndromes. The unique SNV and CNV profiles demonstrate that syndromic adrenocortical tumors may represent a genetically distinct entity from sporadic tumors.

01.01 Development of a Novel Orthotopic Brain Metastasis Patient-Derived Xenograft Model for Breast Cancer

M. Oshi1, M. Okano1, A. L. Butash1, K. Takabe1  1Roswell Park Cancer institute,Department Of Surgical Oncology,Buffalo, NY, USA

Introduction: Despite the fact that the 5-year survival rate for breast cancer(BC) is outstanding compared to other cancers, there are 40,000 deaths annually due to the disease in the US. The vast majority of the mortality results from distant metastasis and therefore pre-clinical models are essential for development of proper and precise treatment for each patient. Patient-derived xenograft (PDX) maintains the features of the donor tumors such as intra-tumor heterogeneity. However, the establishment of an orthotopic metastatic model is still lacking due to procedural difficulty. We demonstrate our novel methods to develop an orthotopic brain metastasis patient-derived xenograft model (PDMOX) for BC brain metastasis.

Methods: PDMOX were created using metastatic brain tumors from BC patients and implanting them in the brain of NSG female mice aged 8-12m through a frontal bone burr hole into the right caudate putamen. Tumors of ~1mm3 were implanted in 2 different forms: single solid piece or mechanically minced tissue with medium.

Results:In the “manual push” method, a minced tumor mixed with 3µl medium is instilled at a depth of 4 mm by using a 23G needle, and a single solid piece of tumor is implanted by using forceps. In the “pipette tip” method, we utilized either a pipette for minced tissue, or a Hamilton syringe with a tip for solid tissue in order to inoculate tumor at the same depth. One hour post-surgical survival after implantation of minced tumor by “manual push” method was only 37.5% (3/8), whereas 100% (30/30) of the mice inoculated with the “pipette tip” method survived. The advantage of the “pipette tip” method was to minimize mechanical forces during inoculation into the brain by using a pipette or tip as a stopper. All tumors were well engrafted in surviving mice in both methods. With the “manual push” method, more tumors formed on the brain surface rather than within the brain parenchyma when compared to the “pipette tip” method. There was a large variation in tumor growth after “manual push”(Median 20±25.0, range: 12-24d. Tumor volume: median 5.6±21.0, range 2.8-48.7mm3). Although 2 out of 3 mice that underwent the “manual push” method had sudden death, all mice that underwent the “pipette tip” method lived until the tumor grew to 125-200mm3 without neurological symptoms. There was no difference in the time of engraftment and tumor growth rate between solid piece and minced tumor tissue using the “pipette tip” method. The success rate of passage for 2nd and 3rd generation was 100% (26/26).

Conclusion:Various surgical techniques used to generate PDMOX BC models showed major differences in the tumors and outcomes. These novel models are expected to become powerful tools for preclinical studies in metastatic BC.